Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback